H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis

PLoS Pathogens

Volumn 8, Issue 9, 2012, Pages

  van der Vries, Erhard ^a   Collins, Patrick J ^b   Vachieri, Sebastien G ^b   Xiong, Xiaoli ^b   Liu, Junfeng ^b,c   Walker, Philip A ^b   Haire, Lesley F ^b   Hay, Alan J ^b   Schutten, Martin ^a   Osterhaus, Albert D M E ^a   Martin, Steve R ^b   Boucher, Charles A B ^a   Skehel, John J ^b   Gamblin, Steve J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^c CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; VIRUS SIALIDASE; ZANAMIVIR;

2009 H1N1 INFLUENZA; ARTICLE; DISSOCIATION CONSTANT; DRUG RECEPTOR BINDING; ENZYME KINETICS; ENZYME STRUCTURE; GENE MUTATION; INFLUENZA VIRUS A H1N1; MUTANT; NONHUMAN; VIRUS RESISTANCE; X RAY CRYSTALLOGRAPHY;

ADAMANTANE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PANDEMICS; PROTEIN CONFORMATION; ZANAMIVIR;

ORTHOMYXOVIRIDAE;

EID: 84866902241     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002914     Document Type: Article

References (41)

1. Kreijtz JH, Osterhaus AD, Rimmelzwaan GF, (2009) Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control. Hum Vaccin 5: 126-135.
2. Kumar D, Michaels MG, Morris MI, Green M, Avery RK, et al. (2010) Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis 10: 521-526.
3. Novel Swine-Origin Influenza AVIT, Dawood FS, Jain S, Finelli L, Shaw MW, et al. (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360: 2605-2615.
4. Varghese JN, Laver WG, Colman PM, (1983) Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 303: 35-40.
5. Colman PM, (2002) Neuraminidase inhibitors as antivirals. Vaccine 20 Suppl 2: S55-58.
6. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, et al. (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363: 418-423.
7. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, et al. (2002) The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 55: 307-317.
8. Herlocher ML, Carr J, Ives J, Elias S, Truscon R, et al. (2002) Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res 54: 99-111.
9. Carr J, Ives J, Kelly L, Lambkin R, Oxford J, et al. (2002) Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 54: 79-88.
10. Meijer A, Lackenby A, Hungnes O, Lina B, van-der-Werf S, et al. (2009) Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 Season. Emerg Infect Dis 15: 552-560.
11. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O, (2009) Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 15: 155-162.
12. van der Vries E, van den Berg B, Schutten M, (2008) Fatal oseltamivir-resistant influenza virus infection. N Engl J Med 359: 1074-1076.
13. Baz M, Abed Y, Simon P, Hamelin ME, Boivin G, (2010) Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis 201: 740-745.
14. Bouvier NM, Lowen AC, Palese P, (2008) Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J Virol 82: 10052-10058.
15. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, et al. (2009) Structural basis for oseltamivir resistance of influenza viruses. Vaccine 27: 6317-6323.
16. Bloom JD, Gong LI, Baltimore D, (2010) Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275.
17. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, et al. (2009) Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
18. van der Vries E, Stelma FF, Boucher CA, (2010) Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 363: 1381-1382.
19. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV, (2010) Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 51: 983-984.
20. Centers for Disease C, Prevention (2009) Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb Mortal Wkly Rep 58: 969-972.
21. van der Vries E, Veldhuis Kroeze EJ, Stittelaar KJ, Linster M, Van der Linden A, et al. (2011) Multidrug resistant 2009 A/H1N1 influenza clinical isolate with a neuraminidase I223R mutation retains its virulence and transmissibility in ferrets. PLoS Pathog 7: e1002276.
22. Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, et al. (2012) Impact of mutations at residue i223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Antimicrob Agents Chemother 56: 1208-1214.
23. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, et al. (2008) Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453: 1258-1261.
24. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, et al. (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443: 45-49.
25. Li Q, Qi J, Zhang W, Vavricka CJ, Shi Y, et al. (2010) The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol 17: 1266-1268.
26. Amaro RE, Swift RV, Votapka L, Li WW, Walker RC, et al. (2011) Mechanism of 150-cavity formation in influenza neuraminidase. Nat Commun 2: 388.
27. Rudrawar S, Dyason JC, Rameix-Welti MA, Rose FJ, Kerry PS, et al. (2010) Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Nat Commun 1: 113.
28. Hurt A, Lee R, Leang S, Cui L, Deng Y, et al. (2011) Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 16: pii: 19884.
29. Seibert CW, Rahmat S, Krammer F, Palese P, Bouvier NM, (2012) Efficient transmission of pandemic H1N1 influenza viruses with high-level oseltamivir resistance. J Virol 86: 5386-9.
30. Fraaij PL, van der Vries E, Beersma MF, Riezebos-Brilman A, Niesters HG, et al. (2011) Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. J Infect Dis 204: 777-782.
31. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG, (2000) A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 97: 6108-6113.
32. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S, (2008) Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog 4: e1000103.
33. Wang ZM, Tai CY, Mendel DB, (2000) Studies on the mechanism by which mutations at His274 alter sensitivity of influenza A virus neuraminidase type 1 to GS4071 and zanamivir. Antiviral Research 46: 81.
34. Garrido-del Solo C, García-Cánovas F, Havsteen BH, Varón Castellanos R, (1999) Kinetic analysis of enzyme reactions with slow-binding inhibition. Biosystems 51: 169-180.
35. Battye TG, Kontogiannis L, Johnson O, Powell HR, Leslie AG, (2011) iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr 67: 271-281.
36. Evans PR, (2011) An introduction to data reduction: space-group determination, scaling and intensity statistics. Acta Crystallogr D Biol Crystallogr 67: 282-292.
37. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, et al. (2007) Phaser crystallographic software. J Appl Crystallogr 40: 658-674.
38. Murshudov GN, Vagin AA, Dodson EJ, (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255.
39. Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr 66: 213-221.
40. Emsley P, Lohkamp B, Scott WG, Cowtan K, (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66: 486-501.
41. Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, et al. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66: 12-21.